GSK's Blenrep Produces Significant Survival Improvement in Relapsed or Refractory Multiple Myeloma

Patients with relapsed or refractory multiple myeloma administered Blenrep combined with bortezomib plus dexamethasone experienced a 59% reduction in the risk of disease progression or death compared with the standard of care.